<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01536795</url>
  </required_header>
  <id_info>
    <org_study_id>A-9768.2</org_study_id>
    <secondary_id>IND50,098</secondary_id>
    <nct_id>NCT01536795</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis</brief_title>
  <official_title>Topical Treatment of Old World Cutaneous Leishmaniasis With WR279396 (Paromomycin/Gentamicin Ointment): Efficacy and Tolerance of a Regimen Using an Occlusive Polyurethane Dressing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Development Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U.S. Army Medical Research and Development Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 study is to determine whether WR279396 with occlusion (a polyurethane dressing)&#xD;
      is more effective than WR279396 without occlusion for once daily treatment.&#xD;
&#xD;
      Extensive objective and subjective local tolerance data will also be captured during this&#xD;
      trial, as well as surrogate markers (parasite loads and aminoglycosides concentration in the&#xD;
      deep dermis) that may help to determine the optimal number and duration of treatments.&#xD;
&#xD;
      The results from this study will help determine the most practical treatment schedule and&#xD;
      will answer questions that are crucial to improve the present treatment regimen with WR279396&#xD;
      which is twice a day for 20 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty-eight patients (48) with Old World cutaneous leishmaniasis will be randomly allocated&#xD;
      to WR279396 treatment once a day for 20 days with an optimized polyurethane dressing&#xD;
      (occlusion) (24 patients), or without occlusion (24 patients). All patients will be rescued&#xD;
      with the standard of care accepted in Tunisia, if the patient is not cured. The active&#xD;
      ingredients of WR279396 are two aminoglycosides - paromomycin sulphate (15%) and gentamicin&#xD;
      sulphate (0.5%) - in a base (AQIC).&#xD;
&#xD;
      Each subject will be followed for clinical cure for 90 days after the initiation of&#xD;
      treatment. Cure is defined as 100% reepithelialization without relapse by 3 months.&#xD;
&#xD;
      Tolerance will be evaluated by local adverse reactions and by laboratory signs of systemic&#xD;
      events.&#xD;
&#xD;
      In addition to the clinical evaluation of the CL lesions, the following parameters/clinical&#xD;
      healing surrogates will be investigated:&#xD;
&#xD;
        1. parasite load will be determined in superficial and deep lesional dermis samples at D0&#xD;
           and D10. The mean parasite reduction ratio (parasite load at D10/parasite load at D0) in&#xD;
           each group will be compared;&#xD;
&#xD;
        2. aminoglycoside concentrations in superficial and deep infiltrated dermis in each group&#xD;
           will be compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2005</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Overview of Adverse Events</measure>
    <time_frame>During 20 day treatment period</time_frame>
    <description>Safety of WR279,396 through the tracking of local, systemic and spontaneous adverse reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Responses of Index Lesions (100% Re-epithelialization)</measure>
    <time_frame>Day 50, 90</time_frame>
    <description>Efficacy will be evaluated in terms of the number of lesions cured at D50 (D1 is the first day of treatment) with no relapse by Day 90. Complete clinical respoonse is defined as 100% re-epithelialization of the index lesion by Day 50 or a &gt; 50% re-epithelialization by Day 50 followed by complete re-epithelialization on or before Day 90, with no relapse ever having occurred from Day 50 through Day 90.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Area of the Index Lesion's Ulceration by Study Day</measure>
    <time_frame>Days 1, 10, 20, 50 and 90</time_frame>
    <description>Area of the index lesion's ulceration over time in mm2</description>
  </other_outcome>
  <other_outcome>
    <measure>Area of the Index Lesion's Induration by Study Day</measure>
    <time_frame>Days 1, 10, 20, 50 and 90</time_frame>
    <description>Area of the index lesion's induration over time in mm2</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage Change in Induration Area From Baseline and Days 10, 20, 50 and 90</measure>
    <time_frame>Days 10, 20, 50 and 90</time_frame>
    <description>Percentage of change of index lesion in induration area from baseline and days 10, 20, 50 and 90</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Old World Cutaneous Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>WR279,396 with Tegaderm dressing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 patients will be randomly allocated to WR279,396 treatment once-a-day for 20 days with using an occlusive polyurethane Tegaderm dressing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WR279,396 with Gauze and Tape Dressing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects will be randomly allocated to WR279,396 treatment once a day for 20 days without an optimized polyurethane dressing (gauze and tape only).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WR279,396 with Tegaderm Dressing</intervention_name>
    <description>Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing</description>
    <arm_group_label>WR279,396 with Tegaderm dressing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WR 279,396 with Gauze and Tape Dressing</intervention_name>
    <description>Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days</description>
    <arm_group_label>WR279,396 with Gauze and Tape Dressing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: The study population will be selected from adults (18y) patients and&#xD;
        children above 15y in Tunisia (Old World)&#xD;
&#xD;
          -  Age: 15 - 75 years old&#xD;
&#xD;
          -  Lesion character: each diameter (horizontal and vertical) of the lesion test must&#xD;
             measure 7 mm, the lesion must be primarily ulcerative (i.e., not verrucous or nodular)&#xD;
             and located in a biopsy friendly site of the body&#xD;
&#xD;
          -  Parasitological diagnosis: have cutaneous leishmaniasis proven parasitologically in&#xD;
             lesion selected for inclusion in study (lesion test).&#xD;
&#xD;
          -  Informed consent: have given written informed consent to participate in the study:&#xD;
             (i.e. patient or legal representative).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Drug intolerance: history of known or suspected hypersensitivity or idiosyncratic&#xD;
             reactions to aminoglycosides in the patient or immediate family members.&#xD;
&#xD;
          -  Previous use of antileishmanial drugs (within 2 months) or present use of routinely&#xD;
             nephrotoxic or ototoxic drugs.&#xD;
&#xD;
          -  Potential for follow up: Have less than 4 months time remaining in present address&#xD;
             and/or plans to leave the area for more than 30 days.&#xD;
&#xD;
          -  Extent of disease: More than 10 lesions or lesion Â³ 5 cm or a lesion less than 2 cm&#xD;
             from eye, in the ear, or a lesion in the face, that in the opinion of the attending&#xD;
             dermatologist could potentially cause significant disfigurement.&#xD;
&#xD;
          -  Location of disease: mucosal involvement.&#xD;
&#xD;
          -  Disseminated disease: clinically significant lymphadenitis with nodules that are&#xD;
             painful and &gt; 1 cm in size in the lymphatic drainage of the ulcer.&#xD;
&#xD;
          -  Concomitant medical problems: significant medical problems of the kidney or liver as&#xD;
             determined by history and by the following laboratory studies:&#xD;
&#xD;
          -  Kidney: clinically significant abnormalities of urine analysis, serum levels of&#xD;
             Creatinine, BUN, total proteins &gt; upper limit of normal for the laboratory.&#xD;
&#xD;
          -  Liver: AST or ALT &gt; upper limit of normal for the laboratory.&#xD;
&#xD;
          -  General: glucose, Na, K, &gt; upper limit of normal or &lt; lower limit of normal for the&#xD;
             laboratory. Volunteers in whom these normal laboratory values are exceeded by less&#xD;
             than 25% will not be automatically excluded. These volunteers will be evaluated on the&#xD;
             basis of history, physical, as well as laboratory values.&#xD;
&#xD;
          -  Scheduled or ongoing pregnancy as determined clinical and biological criteria.&#xD;
&#xD;
          -  Presence of signs or symptoms of peripheral neuropathy, myasthenia gravis or&#xD;
             neuromuscular block&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Afif Ben Salah,, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Pasteur, Tunisia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Pasteur</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 16, 2012</study_first_submitted>
  <study_first_submitted_qc>February 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2012</study_first_posted>
  <results_first_submitted>March 15, 2017</results_first_submitted>
  <results_first_submitted_qc>December 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2021</results_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ointment to treat leishmania skin lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>48 subjects were randomized and received treatment at the Institut Pasteur de Tunis and primary healthcare centers and schools of the study area in Sidi Bouzid and Elmmara, Tunisia.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>WR279,396 With Tegaderm Dressing</title>
          <description>24 patients will be randomly allocated to WR279,396 treatment once-a-day for 20 days with using an occlusive polyurethane Tegaderm dressing&#xD;
WR279,396 with Tegaderm Dressing: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing</description>
        </group>
        <group group_id="P2">
          <title>WR279,396 With Gauze and Tape Dressing</title>
          <description>24 subjects will be randomly allocated to WR279,396 treatment once a day for 20 days without an optimized polyurethane dressing (gauze and tape only).&#xD;
WR 279,396 with Gauze and Tape Dressing: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>WR279,396 With Tegaderm Dressing</title>
          <description>24 patients will be randomly allocated to WR279,396 treatment once-a-day for 20 days with using an occlusive polyurethane Tegaderm dressing&#xD;
WR279,396 with Tegaderm Dressing: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing</description>
        </group>
        <group group_id="B2">
          <title>WR279,396 With Gauze and Tape Dressing</title>
          <description>24 subjects will be randomly allocated to WR279,396 treatment once a day for 20 days without an optimized polyurethane dressing (gauze and tape only).&#xD;
WR 279,396 with Gauze and Tape Dressing: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Middle Eastern or North African</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other (European/Arab)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Tunisia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Subjects with a previous history of leishmaniasis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety: Overview of Adverse Events</title>
        <description>Safety of WR279,396 through the tracking of local, systemic and spontaneous adverse reactions</description>
        <time_frame>During 20 day treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WR279,396 With Tegaderm Dressing</title>
            <description>24 patients will be randomly allocated to WR279,396 treatment once-a-day for 20 days with using an occlusive polyurethane Tegaderm dressing&#xD;
WR279,396 with Tegaderm Dressing: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing</description>
          </group>
          <group group_id="O2">
            <title>WR279,396 With Gauze and Tape Dressing</title>
            <description>24 subjects will be randomly allocated to WR279,396 treatment once a day for 20 days without an optimized polyurethane dressing (gauze and tape only).&#xD;
WR 279,396 with Gauze and Tape Dressing: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Overview of Adverse Events</title>
          <description>Safety of WR279,396 through the tracking of local, systemic and spontaneous adverse reactions</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with atleast 1 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with an SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawals due to an AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not due to an AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Responses of Index Lesions (100% Re-epithelialization)</title>
        <description>Efficacy will be evaluated in terms of the number of lesions cured at D50 (D1 is the first day of treatment) with no relapse by Day 90. Complete clinical respoonse is defined as 100% re-epithelialization of the index lesion by Day 50 or a &gt; 50% re-epithelialization by Day 50 followed by complete re-epithelialization on or before Day 90, with no relapse ever having occurred from Day 50 through Day 90.</description>
        <time_frame>Day 50, 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WR279,396 With Tegaderm Dressing</title>
            <description>24 patients will be randomly allocated to WR279,396 treatment once-a-day for 20 days with using an occlusive polyurethane Tegaderm dressing&#xD;
WR279,396 with Tegaderm Dressing: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing</description>
          </group>
          <group group_id="O2">
            <title>WR279,396 With Gauze and Tape Dressing</title>
            <description>24 subjects will be randomly allocated to WR279,396 treatment once a day for 20 days without an optimized polyurethane dressing (gauze and tape only).&#xD;
WR 279,396 with Gauze and Tape Dressing: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Responses of Index Lesions (100% Re-epithelialization)</title>
          <description>Efficacy will be evaluated in terms of the number of lesions cured at D50 (D1 is the first day of treatment) with no relapse by Day 90. Complete clinical respoonse is defined as 100% re-epithelialization of the index lesion by Day 50 or a &gt; 50% re-epithelialization by Day 50 followed by complete re-epithelialization on or before Day 90, with no relapse ever having occurred from Day 50 through Day 90.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 50 - Not Evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 - Cured</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 - Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 - Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 - Not Evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 - Cured/Improved at D50 with no relapse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 - Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90 - Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area of the Index Lesion's Ulceration by Study Day</title>
        <description>Area of the index lesion's ulceration over time in mm2</description>
        <time_frame>Days 1, 10, 20, 50 and 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WR279,396 With Tegaderm Dressing</title>
            <description>24 patients will be randomly allocated to WR279,396 treatment once-a-day for 20 days with using an occlusive polyurethane Tegaderm dressing&#xD;
WR279,396 with Tegaderm Dressing: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing</description>
          </group>
          <group group_id="O2">
            <title>WR279,396 With Gauze and Tape Dressing</title>
            <description>24 subjects will be randomly allocated to WR279,396 treatment once a day for 20 days without an optimized polyurethane dressing (gauze and tape only).&#xD;
WR 279,396 with Gauze and Tape Dressing: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area of the Index Lesion's Ulceration by Study Day</title>
          <description>Area of the index lesion's ulceration over time in mm2</description>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.0" spread="147.39"/>
                    <measurement group_id="O2" value="157.69" spread="179.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.87" spread="106.41"/>
                    <measurement group_id="O2" value="140.64" spread="157.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.62" spread="101.45"/>
                    <measurement group_id="O2" value="153.51" spread="176.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="48.3"/>
                    <measurement group_id="O2" value="1.3" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8" spread="117.9"/>
                    <measurement group_id="O2" value="0.00" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area of the Index Lesion's Induration by Study Day</title>
        <description>Area of the index lesion's induration over time in mm2</description>
        <time_frame>Days 1, 10, 20, 50 and 90</time_frame>
        <population>On D50 in the Gauze-Tape group no SD was given in the data table. All good cause efforts to locate the data for Day 50 SD value for gauze and tape dressing arm have been exhausted, data are missing and hence not available to be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>WR279,396 With Tegaderm Dressing</title>
            <description>24 patients will be randomly allocated to WR279,396 treatment once-a-day for 20 days with using an occlusive polyurethane Tegaderm dressing&#xD;
WR279,396 with Tegaderm Dressing: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing</description>
          </group>
          <group group_id="O2">
            <title>WR279,396 With Gauze and Tape Dressing</title>
            <description>24 subjects will be randomly allocated to WR279,396 treatment once a day for 20 days without an optimized polyurethane dressing (gauze and tape only).&#xD;
WR 279,396 with Gauze and Tape Dressing: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area of the Index Lesion's Induration by Study Day</title>
          <description>Area of the index lesion's induration over time in mm2</description>
          <population>On D50 in the Gauze-Tape group no SD was given in the data table. All good cause efforts to locate the data for Day 50 SD value for gauze and tape dressing arm have been exhausted, data are missing and hence not available to be reported.</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0/1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360.7" spread="262.5"/>
                    <measurement group_id="O2" value="505.9" spread="431.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405.14" spread="250.78"/>
                    <measurement group_id="O2" value="495.25" spread="401.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410.15" spread="269.62"/>
                    <measurement group_id="O2" value="468.85" spread="344.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.7" spread="249.8"/>
                    <measurement group_id="O2" value="148.05" spread="NA">All good cause efforts to locate the data have been exhausted, data are missing and hence not available to be reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" spread="235.4"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage Change in Induration Area From Baseline and Days 10, 20, 50 and 90</title>
        <description>Percentage of change of index lesion in induration area from baseline and days 10, 20, 50 and 90</description>
        <time_frame>Days 10, 20, 50 and 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WR279,396 With Tegaderm Dressing</title>
            <description>24 patients will be randomly allocated to WR279,396 treatment once-a-day for 20 days with using an occlusive polyurethane Tegaderm dressing&#xD;
WR279,396 with Tegaderm Dressing: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing</description>
          </group>
          <group group_id="O2">
            <title>WR279,396 With Gauze and Tape Dressing</title>
            <description>24 subjects will be randomly allocated to WR279,396 treatment once a day for 20 days without an optimized polyurethane dressing (gauze and tape only).&#xD;
WR 279,396 with Gauze and Tape Dressing: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Induration Area From Baseline and Days 10, 20, 50 and 90</title>
          <description>Percentage of change of index lesion in induration area from baseline and days 10, 20, 50 and 90</description>
          <units>% change in induration</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3" spread="63.2"/>
                    <measurement group_id="O2" value="45.0" spread="114.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" spread="62.0"/>
                    <measurement group_id="O2" value="51.0" spread="116.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.4" spread="78.5"/>
                    <measurement group_id="O2" value="-83.9" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65.1" spread="98.5"/>
                    <measurement group_id="O2" value="-100.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>WR279,396 With Tegaderm Dressing</title>
          <description>24 patients will be randomly allocated to WR279,396 treatment once-a-day for 20 days with using an occlusive polyurethane Tegaderm dressing&#xD;
WR279,396 with Tegaderm Dressing: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing</description>
        </group>
        <group group_id="E2">
          <title>WR279,396 With Gauze and Tape Dressing</title>
          <description>24 subjects will be randomly allocated to WR279,396 treatment once a day for 20 days without an optimized polyurethane dressing (gauze and tape only).&#xD;
WR 279,396 with Gauze and Tape Dressing: Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Local reaction (infection at biopsy site)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Any infection and infestation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Any investigations</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister (vesicles)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dermatitis contact (allergy to Tegaderm)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Afif Ben Salah, MD</name_or_title>
      <organization>Institut Pasteur, Tunisia</organization>
      <phone>011-216-71-792-429</phone>
      <email>afif.bensalah@pateur.rns.tn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

